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ABSTRACT: Legius syndrome presents as an autosomal dominant condition characterized by café-
au-lait macules with or without freckling and sometimes a Noonan-like appearance and/or learning 
difficulties. It is caused by germline loss-of-function SPRED1 mutations and is a member of the 
RAS-MAPK pathway syndromes. Most mutations result in a truncated protein and only a few 
inactivating missense mutations have been reported. Since only a limited number of patients has 
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been reported up until now, the full clinical and mutational spectrum is still unknown. We report 
mutation data and clinical details in fourteen new families with Legius syndrome. Six novel 
germline mutations are described. The Trp31Cys mutation is a new pathogenic SPRED1 missense 
mutation. Clinical details in the 14 families confirmed the absence of neurofibromas, and Lisch 
nodules, and the absence of a high prevalence of central nervous system tumors. We report white 
matter T2 hyperintensities on brain MRI scans in 2 patients and a potential association between 
postaxial polydactyly and Legius syndrome.   ©2010 Wiley-Liss, Inc. 
KEY WORDS: Legius syndrome, SPRED1, NF1, RAS-MAPK pathway, polydactyly 
 
INTRODUCTION 
  Legius syndrome (MIM# 611431) was recently identified as a Neurofibromatosis type 1 (NF1)- like 
syndrome caused by heterozygous germline loss-of-function SPRED1 (MIM# 609291) mutations (Brems et al., 
2007). In the original report five families with an autosomal dominant inherited condition presenting with multiple 
café-au-lait macules (CALM), axillary freckling, macrocephaly and at times a Noonan-like facial appearance were 
described. Learning difficulties and/or attention deficit were observed in several children and multiple lipomas 
were present in several adults. Some typical NF1 (MIM# 162200) features such as Lisch nodules of the iris, 
neurofibromas and central nervous system tumors were systematically absent.  
Pasmant et al. identified five probands with a SPRED1 mutation in 61 index cases. They confirmed a high 
prevalence of CALM, freckling and learning disability as well as absence of neurofibromas and Lisch nodules 
(Pasmant et al., 2009b). Noonan-like dysmorphism was not observed and macrocephaly was reported in only one 
individual. Lipomas were seen in one family. Spurlock et al. identified 6 probands with SPRED1 mutations in 85 
unrelated patients referred for NF1 gene (MIM# 613113) testing who were NF1 mutation negative and had no 
cutaneous neurofibromas (Spurlock et al., 2009). All affected probands but 1 satisfied NF1 diagnostic criteria. 
They all had CALM. None had Noonan-like features, macrocephaly, Lisch nodules or cutaneous neurofibromas. 
No significant developmental or learning problems were observed. 
Messiaen et al. performed a genotype-phenotype study in 22 unrelated probands carrying a SPRED1 mutation 
identified through clinical testing (Messiaen et al., 2009). Fifty percent of SPRED1 positive individuals fulfilled 
NF1 NIH diagnostic criteria based on the presence of more than 5 CALM with or without freckling or a NF1 
family history. Symptomatic optic pathway gliomas, neurofibromas or typical NF1 osseous lesions were absent in 
the affected individuals and there was no increased prevalence of lipomas. Relative macrocephaly was documented 
in 27% of individuals and language/speech difficulties in 25% of children. In a second cross-sectional study 
Messiaen et al. performed SPRED1 mutation analysis in 1318 unrelated patients presenting with a broad range of 
signs typical for NF1 but no detectable NF1 mutation (Messiaen et al., 2009). They identified 26 pathogenic 
SPRED1 mutations in 33 probands and 7 probable non-pathogenic missense mutations in 9 probands. A SPRED1 
mutation detection rate of 19% was found in families with an autosomal dominant phenotype of CALM with or 
without freckling and no other NF1 features. Muram-Zborovski et al. sequenced the SPRED1 gene in 151 
individuals with a clinical diagnosis of NF1 and identified 2 SPRED1-positive individuals. They both had multiple 
CALM, intertriginous freckling, learning difficulties and absence of neurofibromas (Muram-Zborovski et al., 
2010).  
The SPRED1 gene is a relatively small gene (7 coding exons) located on chromosome 15q14. Most germline 
mutations truncate the protein, but two pathogenic missense mutations and one in-frame deletion have been 
reported. Similar to neurofibromin, the protein product of NF1, SPRED1 is a negative regulator of RAS-MAPK 
signalling. Whereas neurofibromin acts as a GTP-ase activating protein that accelerates conversion of active GTP-
bound RAS to inactive GDP-bound RAS, SPRED1 is believed to act at the level of RAS-RAF interaction 
(Wakioka et al., 2001). Both syndromes thus belong to the group of RAS-MAPK pathway disorders or neuro-
cardio-facial-cutaneous (NCFC) syndromes (Bentires-Alj et al., 2006; Denayer et al., 2008). Different degrees of 
cognitive impairment and tumor predisposition are associated with these syndromes. In Legius syndrome one 
occurrence each of non-small cell lung cancer, Wilms tumor, tubular colon adenoma, (Brems et al., 2007) acute 
myeloblastic anemia,(Pasmant et al., 2009a; Pasmant et al., 2009b) tenosynovial giant cell tumor, breast cancer 
and dermoid tumor of the ovary (Messiaen et al., 2009) has been reported. No causal relationship with the germline 
SPRED1 mutation has been proven in any of these cases. Whether Legius syndrome is associated with an 
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increased risk for a specific range of malignancies remains unknown. Messiaen et al. estimated that a study of 250 
adult patients would be needed to detect rare complications with a prevalence of only 1% (Messiaen et al., 2009). 
Therefore it remains important to report on new cases of Legius syndrome.  
In this study the clinical data of fourteen new probands with Legius syndrome and their affected relatives are 
described. One missense mutation was characterized functionally.  
MATERIALS AND METHODS 
Study population 
After publication of the first report, SPRED1 mutation analysis was performed in the Department of Human 
Genetics, Catholic University of Leuven, Belgium in 35 probands with a NF1-like syndrome. DNA samples 
included patients followed in the Leuven neurofibromatosis clinic as well as samples sent by clinical geneticists 
from other centres in Belgium or from abroad. Clinical data of 6 affected probands and their relatives carrying a 
mutation were collected by an extended phenotypical checklist (families 6, 7, 10, 11, 12, 14). In addition clinical 
data of eight other SPRED1-mutation positive families were obtained. Mutation analysis for these cases was 
performed in the Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands (families 
1, 2, 3, 5, 8, 9, 13) and in the Medical Genetics Centre, Munich, Germany (family 4). Most of these cases showed a 
phenotype compatible with Legius syndrome: presence of CALM and freckling and absence of neurofibromas and 
several had been tested before for NF1 mutations.  
Brain imaging data were available for 10 patients (9 MRI, 1 CT).  
Height and head circumference at a given age were converted to standard deviations using the growth charts of 
Flanders 2004 (http://www.vub.ac.be/groeicurven) and Roelants et al., 2009. An individual was recorded as 
macrocephalic when head circumference was 2 standard deviations above the mean. An individual was recorded to 
have relative macrocephaly when head circumference was above 2 standard deviations at the age when height 
would have been at the mean.  
 
Mutation analysis 
Mutation analysis was performed as reported before (Brems et al., 2007). Mutation numbering was based on the 
cDNA sequence with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence 
(GenBank accession code: NM_152594.2). For protein numbering the initiation codon is codon 1 (NP_689807.1). 
Names of all variants were checked using the Mutalyzer program (http://www.LOVD.nl/mutalyzer/).  
Amino acid conservation for a novel missense mutation was evaluated with the Conseq program 
(http://conseq.tau.ac.il/). Bio-informatical prediction of the possible impact of the missense change on the SPRED1 
protein was performed with Polyphen (http://genetics.bwh.harvard.edu/pph/). 
Mutation analysis in DNA extracted from paraffin-embedded tissue from a vestibular schwannoma was 
performed with a different set of primers resulting in smaller amplicons.  
 
Functional analyses 
Wild-type SPRED1 cDNA was cloned into a pcDNA3.1 (Invitrogen) construct encoding an N-terminal Flag-
tag. SPRED1 mutant p.Trp31Cys was generated by PCR-directed mutagenesis and verified by sequencing. Wild-
type and mutant SPRED1 constructs were subcloned in a pmax vector (Amaxa Biosystems). The GAL4/Elk-1 
reporter assay was performed as described before (Messiaen et al., 2009). The Elk-1 transcription factor is a 
substrate for phosphorylation by the activated MAPK pathway. In the GAL4/Elk-1 reporter assay luciferase 
activity is measured in HEK293T cells co-transfected with pFA-Elk1, pFR-Luc, β-galactosidase and Flag-tagged 
SPRED1 constructs after stimulation with epidermal growth factor (EGF). 
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RESULTS 
Mutation analysis 
Twelve different truncating SPRED1 mutations were found in 13 unrelated probands: 7 frameshift and 5 
nonsense mutations, 11/13 cases were familial. A missense mutation was found in proband 3 and occurred de 
novo. Mutation analysis of DNA extracted from peripheral blood of both parents of proband 3 showed only wild 
type SPRED1 sequence. An overview of the different mutations is given in Table 1. Six mutations had not been 
reported as germline mutations in the literature before (c.93G>T, p.Trp31Cys; c.304dupA, p.Thr102AsnfsX7; 
c.360dupA, p.Glu121ArgfsX13; c.576_580dup, p.Gln194ProfsX4; c.940C>T, p.Gln314X; c.1045_1046del,  
p.Arg349GlyfsX4). Trp31 is a highly conserved amino acid residue (Conseq score 7, conserved in Bos Taurus, 
Mus musculus, Gallus gallus, Xenopus tropicalis, Danio rerio, Drosophila melanogaster). Bio-informatic analysis 
using Polyphen software predicts the p.Trp31Cys mutation to be probably damaging. It may disrupt the function of 
the EVH1 domain. In the Elk-1 reporter assay overexpression of wild-type SPRED1 efficiently inhibited the 
activation of the MAPK pathway after stimulation of the cells with EGF resulting in low luciferase activity. The 
Trp31Cys SPRED1 mutant was unable to suppress the EGF induced Elk-1 dependent transcription activation 
confirming that this is an inactivating and therefore pathogenic mutation. (Figure 1) 
 
Table 1. SPRED1 mutations in fourteen families with Legius syndrome 
 
Family Exon Nucleotide change Amino acid change Inheritance 
1 3 c.52C>T p.Arg18X sporadicb 
2 3 c.70C>T p.Arg24X familial 
3 3 c.93G>T p.Trp31Cys de novo 
4 3 c.190C>T p.Arg64X familial 
5 3 c.190C>T p.Arg64X sporadicb 
6 4 c.304dupAa p.Thr102AsnfsX7 familial 
7 4 c.326_329dup p.Arg110SerfsX2 familial 
8 4 c.349C>T p.Arg117X familial 
9 4 c.360dupA p.Glu121ArgfsX13 familial 
10 6 c.576_580dup p.Gln194ProfsX4 familial 
11 8 c.940C>T p.Gln314X familialb 
12 8 c.1045_1046del p.Arg349GlyfsX11 familial 
13 8 c.1048_1060del p.Gly350MetfsX52 familial 
14 8 c.1149_1152del p.Gly385IlefsX20 familial 
 
Mutation numbering was based on the cDNA sequence with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence (GenBank accession code: NM_152594.2). For protein numbering the 
initiation codon is codon 1 (NP_689807.1). 
Bold: novel mutations  
a: This mutation has already been reported as a somatic mutation in melanocytes of a patient with Legius syndrome 
b: no DNA from family members available to prove sporadic or familial occurrence of the mutation 
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Figure 1. Elk-1 quantitative luciferase assay for Erk activation. Empty vector or vector carrying wild-type (WT; as a control) or 
mutant SPRED1 (Trp31Cys, W31C; Thr102Arg, T102R; Ile81del, I81del) were transfected into HEK293T cells along with 
Elk-1 reporter plasmids. Elk-1 activation is measured as an increase in luciferase activity after stimulation with EGF. Three 
different amounts of plasmids were transfected: 0.05µg, 0.1µg and 0.2 µg. The bars represent the average increase in luciferase 
activity of 3 replicates and error bars represent the standard deviation. Wild-type SPRED1 vector efficiently suppresses EGF 
induced Elk-1 activation in comparison to empty vector. Similar to the known pathogenic Thr102Arg and Ile81del mutations, 
Trp31Cys is unable to downregulate the increase in luciferase activity after EGF stimulation. 
 
 
Phenotype in patients with germline SPRED1 mutations 
Clinical information was obtained for 14 probands and 16 affected relatives. Phenotypic features are 
summarized in Table 2. All individuals had more than 5 CALM, except for two adults from the same family who 
had none. Freckling was present in 10/27 individuals, macrocephaly in 1/24, relative macrocephaly in 2/24. In 
20/24 individuals the head circumference was on a higher percentile than the height. Lisch nodules were 
systematically absent in those patients who had been investigated ophthalmologically (17/30). Neurofibromas were 
not observed, lipomas were present in 2/15 adults. Information regarding psychomotor development was only 
available for 17 patients. Five children had motor delay, 5 children delayed speech. Learning difficulties were 
mentioned in 14/25 individuals. Three individuals were diagnosed with ADHD; in a fourth individual 
hyperactivity and attention deficit were noticed, but there was no formal diagnosis of ADHD; one patient had 
attention deficit without hyperactivity (ADD). In another child concentration problems were noted. In 7 patients 
the diagnosis of Noonan syndrome was considered previously and in 20 patients the diagnosis of NF1 was 
suspected. Sixteen patients fulfil the NF1 NIH diagnostic criteria based on the presence of more than 5 CALM 
with or without freckling and a positive family history. One patient had a desmoid tumor of the abdominal wall. A 
vestibular schwannoma had developed after the age of 50 in patient I1 of family 11. She was said to have the same 
pigmentary findings as her daughter and granddaughter, but had not been examined clinically. SPRED1 mutation 
analysis was conducted on paraffin-embedded tissue from this vestibular schwannoma. In this tissue the familial 
SPRED1 germline mutation was confirmed, but no somatic second hit was found in SPRED1. T2 hyperintense 
spots in the subcortical white matter were observed on brain MRI in 2 patients. (Figure 2)  Other findings were 
epilepsy and Parkinsons disease (n=1), unilateral postaxial hexadactyly (n=2), Chiari malformation with 
syringomyelia (n=1), scoliosis (n=4) with block vertebra (n=1), sensorineural hearing loss (n=1), asymptomatic 
arachnoid cyst detected by brain MRI (n=1), congenital hypothyroidism (n=1). One patient had a clinical diagnosis 
of Marfan syndrome, which was confirmed by a pathogenic mutation in the FBN1 gene (c.3757C>T, 
p.Gln1253X). 
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Figure 2. T2 weighed sagittal secion of brain MRI of patient I1 family 11: T2 hyperintense spot is present in the frontal white 
matter (arrow). 
 
DISCUSSION 
We report on the second largest series of families with Legius syndrome. In this report we describe 30 new 
individuals from 14 families. Our results confirm previous findings that Legius syndrome is characterized by the 
presence of CALM with or without freckling and the absence of typical NF1 complications such as Lisch nodules 
and neurofibromas. In a subset of patients we find Noonan-like facial features (n=12) and/or sternal abnormalities 
(n=7; one of these patients had an additional diagnosis of Marfan syndrome, which is also associated with sternal 
abnormalities). No congenital vascular malformations were present in this cohort. One vestibular schwannoma and 
one benign tumor of the abdominal wall (desmoid tumor) were observed. Both tumor types had not been reported 
before in association with Legius syndrome and it is unclear whether there is a causal relationship between these 
tumors and the germline SPRED1 mutation. Learning difficulties were mentioned in 14/25 patients (56%), three 
patients were diagnosed with ADHD and one with ADD. Combining the data in the literature with that of the 
current  report (142 individuals) learning difficulties were observed in 26 individuals (18.3%) with Legius 
syndrome, delayed psychomotor development (mostly confined to specific speech delay) in 13 (9.2%), and 
hyperactivity, attention problems or ADHD in 14 (9.9%). Whether Legius syndrome is associated with a specific 
neurocognitive profile warrants further investigation.  
Focal areas of high signal intensity on T2-weighed or FLAIR images of brain MRI, also denoted UBOs 
(Unidentified Bright Objects), are found in about 70% of children with NF1 (Gill et al., 2006; North, 2000). UBOs 
occur most often in the basal ganglia, cerebellum, thalamus, brainstem and subcortical white matter. They are not 
associated with focal neurological deficits, but the pathological correlate remains controversial (North, 2000). The 
number and intensity of UBOs diminish with age in the basal ganglia, cerebellum, brainstem and thalamus, 
whereas lesions in the cerebral hemispheres and hippocampus do not change in prevalence over time, suggesting a 
different pathologic background (Gill et al., 2006). There is no consensus on the relationship between UBOs and 
cognitive impairment in NF1. We report two patients (one child and one 39 years old woman) with Legius 
syndrome and aspecific T2 hyperintense lesions on brain MRI. Thus the presence of such a lesion cannot be used 
to exclude the diagnosis of Legius syndrome. However at an adult age these lesions are aspecific and not 
uncommon in the general population. To gain better insight into the prevalence of these and other structural brain 
lesions in patients with Legius syndrome it would be interesting to systematically perform brain MRI in all patients 
in whom the diagnosis is made.  
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Table 2. Clinical features in 14 families with Legius syndrome 
Patient Age 
(y)/ 
gender 
CALM Freckling Height: 
SD 
Head 
circum-
ference: 
SD 
Dysmorphic 
features 
Psychomotor 
development 
Learning 
difficulties 
Behavioral 
problems 
Type of 
education 
Other 
diagnosis 
considered 
Other 
Family 
1 
I1 12/F >5 inguinal +0.65 +0.76 Hypertelorism Normal Dyslexia, 
mathematics 
No Special NF1 Congenital 
hypothyroidism 
Family 
2 
I1 51/M >5 None -2.16 +1.94 None U No Rigid, sad, 
drowsy as 
consequence 
of 
Parkinsonism 
Normal No Generalized 
epilepsy since 
age 39y, 
Parkinson 
disease since age 
45y, MRI: 
lesions nucleus 
caudatus, relative 
macrocephaly, 
Surinamese-
Indian origin 
II1 18/M >5 Axillary -1.76 +1.33 Low posterior 
hairline 
Normal Speech 
problems 
Concentration 
problems and 
hyperactive, 
no diagnosis 
of ADHD 
Normal NF1 Relative 
macrocephaly, 
Surinamese-
Indian origin 
Family 
3 
I1 15/M >5 None +0.62 +1.55 Hypertelorism, 
downslanting 
palpebral 
fissures, 
ptosis, low 
implanted 
posteriorly 
rotated ears, 
low posterior 
hairline, mild 
Motor and 
language 
delay 
Yes ADHD Special NF1 Eczema first 
year, asthma, 
strabismus 
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Patient Age 
(y)/ 
gender 
CALM Freckling Height: 
SD 
Head 
circum-
ference: 
SD 
Dysmorphic 
features 
Psychomotor 
development 
Learning 
difficulties 
Behavioral 
problems 
Type of 
education 
Other 
diagnosis 
considered 
Other 
pterygium 
colli, pectus 
carinatum/ 
excavatum 
Family 
4 
I1 36/F >5 None -1.18 +0.94 None U No No Normal No 5 spontaneous 
abortions, 1 
stillbirth at 6m 
pregnancy, 
unilateral 
postaxial 
polydactyly foot 
II1 3/M >5 None -2.57 -0.97 Downslanting 
palpebral 
fissures, 
ptosis, low 
implanted 
posteriorly 
rotated ears, 
widely spaced 
nipples 
Considerable 
psychomotor 
delay in all 
fields, 
especially 
speech 
/ Attention 
deficit, no 
hyperactivity 
noted 
Special 
kinder-
garten 
NF1, 
Noonan 
Born preterm 
(32w) due to 
IUGR and 
placental 
insufficiency, 
unilateral 
postaxial 
polydactyly hand 
without bony 
structures 
Family 
5 
I1 11/M >5 Axillary, 
inguinal 
-2.33 +0.54 Hypertelorism, 
pectus 
excavatum 
Delayed 
motor 
milestones 
Non-verbal 
learning 
disorder 
No Normal NF1, 
Noonan 
 
Family 
6 
I1 40/F >5 U U U U U Yes U Normal No Desmoid tumor 
abdominal wall 
II1 1/F 13 U U U U U / U / NF1 Dizygotic twin 
Family 
7 
I1 58/F None None  -2.27 +0.65 Low U U U U No Hysterectomy 
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Patient Age 
(y)/ 
gender 
CALM Freckling Height: 
SD 
Head 
circum-
ference: 
SD 
Dysmorphic 
features 
Psychomotor 
development 
Learning 
difficulties 
Behavioral 
problems 
Type of 
education 
Other 
diagnosis 
considered 
Other 
implanted 
ears, 
proöptosis, 
coarse facial 
features 
II1 37/F None None +0.27 +1.35 None Normal Yes, 
mathematics 
U U No Obesity 
III1 11/F >5 Axillary -1 +0,06 Pectus 
excavatum 
Normal Yes, 
mathematics 
ADHD Normal, 
FSIQ: 85, 
VIQ: 93, 
PIQ: 80 
NF1, 
Noonan 
Placental 
insufficiency, 
oligohydramnios, 
dysmaturity, 
transient 
trombopenia 
neonatally, Brain 
MRI: bilateral 
temporal 
subcortical white 
matter lesions 
(T2 
hyperintense) 
Family 
8 
III1 39/F >5 None +0.09 -0.12 Mild 
synophris 
Normal No No Normal NF1 Migraine, some 
skintags in neck 
and face 
III6* 36/M >5 None +1.2 +0.17 Downslanting 
palpebral 
fissures, high-
arched palate, 
protruding 
ears 
Normal No No Normal NF1 Motoric 
clumsiness, mild 
lumbal scoliosis, 
varices L lower 
leg  
IV1 13/M >5 None -0.75 +1.12 Telecanthus, 
low implanted 
ears with thick 
helix 
Normal No No Normal NF1, 
Noonan 
Immature motor 
skills, 
physiologic 
tremor 
IV3 9/M >5 None -0.45 +0.25 Hypertelorism, Normal Yes, No Normal NF1, Immature motor 
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Patient Age 
(y)/ 
gender 
CALM Freckling Height: 
SD 
Head 
circum-
ference: 
SD 
Dysmorphic 
features 
Psychomotor 
development 
Learning 
difficulties 
Behavioral 
problems 
Type of 
education 
Other 
diagnosis 
considered 
Other 
low implanted, 
posteriorly 
rotated ears 
with thick 
helix, short 
neck, mild 
webbing 
mathematics, 
one doublure 
Noonan skills 
Family 
9 
II1 6/M >5 None +3 +0.19 Epicanthal 
folds, ptosis, 
pectus 
carinatum 
Normal Yes No Special NF1 Marfan 
syndrome caused 
by pathogenic 
FBN1 mutation 
(c.3757C>T,  
p.Gln1253X), 
prolapse of 
mitral and 
tricuspid valve, 
wide aortic root 
Family 
10 
II1 19/M several None -0.23 -1.21 Maxillary and 
malar 
hypoplasia, 
prognathism, 
downslanting 
palpebral 
fissures 
Walked at 
18m, 
required 
speech 
therapy 
Mild No Normal 
(university) 
No  
II2 15/M >5 Minimal 
axillary 
-0.77 +0.6 Maxillary and 
malar 
hypoplasia, 
prognathism, 
Noonan facies, 
downslanting 
palpebral 
fissures, 
General 
delay 
Mild No Normal NF1, 
TWIST, 
FGFR3 
Chiari 1 
malformation 
with 
syringomyelia 
with secondary 
scoliosis, normal 
echocardiogram 
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Patient Age 
(y)/ 
gender 
CALM Freckling Height: 
SD 
Head 
circum-
ference: 
SD 
Dysmorphic 
features 
Psychomotor 
development 
Learning 
difficulties 
Behavioral 
problems 
Type of 
education 
Other 
diagnosis 
considered 
Other 
pectus 
excavatum 
II5 12/M Many None -2 -0.07 Malar 
hypoplasia, 
prognathism, 
low set ears, 
downslanting 
palpebral 
fissures, high 
narrow palate 
U Mild No  Normal No  
II6 10/F Many None -1.47 -0.33 Malar 
hypoplasia, 
prognathism, 
long narrow 
face 
Speech 
therapy 
Mild No Normal No  Thoracic 
scoliosis 
requiring surgery 
Family 
11 
I1 39/F >5 Axillary, 
inguinal 
U +2.41 Hypertelorism, 
broad nasal 
bridge, small 
nose tip, large 
mouth with 
thick underlip, 
upslanting 
palpebral 
fissures 
U Concentration 
problems 
No Normal NF1 Congenital 
scoliosis, block 
vertebra L4-L5, 
sensorineural 
hearing loss, 
frequent 
headaches, Brain 
MRI: white 
matter lesions 
frontal and 
temporo-
occipital (T2 
hyperintense) 
Family 
12 
I1 38/M >5 General -2.32 +0.28 No U No No Normal No  
II1 12/M >5 None +0.19 +0.44 No Normal No Anxiety, 
suspicion of 
autism 
Normal NF1  
E1996  Denayer et al. 
Patient Age 
(y)/ 
gender 
CALM Freckling Height: 
SD 
Head 
circum-
ference: 
SD 
Dysmorphic 
features 
Psychomotor 
development 
Learning 
difficulties 
Behavioral 
problems 
Type of 
education 
Other 
diagnosis 
considered 
Other 
II2 8/M >5 Inguinal +0.4 +1 No Normal No No Normal NF1  
Family 
13 
I1 48/M >5 None -2 -1.5 Hypertelorism, 
ptosis, low 
implanted 
posteriorly 
rotated ears, 
widely spaced 
nipples, pectus 
excavatum 
U U U U NF1, 
Noonan 
lipomas 
II1 15/M >5 None -2.71 +0.44 Hypertelorism, 
low implanted 
posteriorly 
rotated ears, 
pectus 
excavatum 
U No ADHD Normal NF1, 
Noonan 
Laryngomalacia, 
cubitus valgus, 
lipomas 
Family 
14 
I1* 74/F >5? U U U U U U U U U Unilateral 
vestibular 
schwannoma 
after age 50y 
II1 48/F >5 Axillary, 
inguinal 
-1.18 U No U No No Normal NF1 Brain MRI: 
asymptomatic 
arachnoid cyst 
right temporal 
lobe 
III1 20/F >5 Axillary, 
inguinal 
-0.27 U No Normal No No Normal NF1  
SD: standard deviation; U: unknown; L: left; R: right; MRI: magnetic resonance imaging; ADHD: attention deficit hyperactivity disorder; FSIQ: full-scale intelligence quotient; 
VIQ: verbal intelligence quotient; PIQ: performance intelligence quotient; IUGR: intrauterine growth retardation 
*: clinical phenotype present, but no mutation analysis performed in this patient
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Unilateral postaxial polydactyly has been observed both by Messiaen et al. (in one case) and in this report (two 
cases) to be associated with Legius syndrome. Combining the data in the literature with that of the current report 
clinical details of 142 individuals with a SPRED1 mutation have been described (Brems et al., 2007; Messiaen et 
al., 2009; Muram-Zborovski et al., 2010; Pasmant et al., 2009b; Spurlock et al., 2009). According to the 
EUROCAT data the prevalence of any type of polydactyly at birth in the European member states was 8.11 cases 
per 10000 births in the 2000-2007 period. The highest prevalence in a specific region of the European Union in 
that time frame was 15 cases per 10000 births (Strasbourg, France). Comparing the prevalence of polydactyly in 
Legius syndrome (3/142) with the maximal birth prevalence in the European Union (15/10000) results in a 
significant difference (p= .0014 for 3 or more cases in a group of 142, binomial distribution). It is interesting to 
note that a similar figure was reported in an Italian study in children with NF1. Ruggieri et al. reported polydactyly 
in 4 children in a total group of 135 children with NF1(Ruggieri et al., 1999).  
Germline SPRED1 mutations are found in all exons of the gene and although some recurrent mutations have 
been reported, no clear mutational hotspots are present. The majority of reported SPRED1 mutations are predicted 
to result in a premature stop codon (nonsense, frameshift, splice-site, out-of-frame insertions and deletions). One 
in-frame deletion and 11 different missense mutations have been reported. By means of functional analyses 2 
missense mutations were classified as pathogenic and 7 as rare benign variants.(Messiaen et al., 2009).  Two 
missense mutations were not characterized (Pasmant et al, 2009b, Spurlock et al., 2009). We characterized an 
additional missense mutation and classify this Trp31Cys mutation as pathogenic based on de novo occurrence in 
the family, amino acid conservation and functional analysis.  
Combining the data in this report and previous publications, one can conclude that the highest chances of 
finding a SPRED1 mutation are in familial cases of CALM with or without freckling. Sporadic cases of CALM are 
more likely due to mosaicism for NF1(Kehrer-Sawatzki and Cooper, 2008). Although the diagnosis of NF1 is 
made clinically based on the NIH criteria, the importance of mutation analysis for genetic counselling is increasing 
with the discovery of allelic and non-allelic NF1 variants. Especially in young children the diagnosis of NF1 can 
be difficult since only approximately half of children with NF1 and no known family history meet the NIH criteria 
by age one year, because many features of NF1 increase in frequency with age. The more general availability of 
NF1 mutation analysis allows for more general use of NF1 mutation testing also in young children. Children with 
typical multiple CALM who test negative for NF1 are candidates for SPRED1 mutation analysis. In sporadic cases 
the yield will be low (2.4%)(Messiaen et al., 2009). In children testing negative for mutations in both NF1 and 
SPRED1 mosaicism for NF1 should be suspected (Maertens et al., 2007). As has been shown in this and previous 
reports Legius syndrome is associated with a milder phenotype than NF1. Likewise a mild NF1 variant associated 
with a 3-basepair inframe deletion of exon 17 (c.2970-2972 delAAT) has been described in which neurofibromas 
are rare and multiple CALM may be the only apparent manifestation (Upadhyaya et al., 2007). In contrast, patients 
with a microdeletion of the NF1 region tend to have a more severe phenotype associated with large numbers and 
more early appearance of cutaneous neurofibromas, a higher risk for development of malignant peripheral nerve 
sheath tumors, more severe cognitive impairment and sometimes somatic overgrowth with large hands and feet 
and dysmorphic facial features (Mensink et al., 2006). 
In conclusion, we report clinical details of 30 probands from 14 families with pathogenic SPRED1 mutations. 
Six novel germline mutations were found. The p.Trp31Cys missense mutation is a pathogenic missense mutation. 
Our results confirm previous reports that Legius syndrome shares clinical features with NF1 but has a milder 
phenotype, although serious problems can be present such as learning difficulties. Therefore we can recommend 
less stringent surveillance of these patients than for patients with NF1. We would recommend routine screening for 
developmental delays and behavioural and learning problems. However physical examination by a clinical 
geneticist or physician familiar with Legius syndrome every 3 years during childhood seems sufficient. A possible 
association with polydactyly is suggested by the finding of two cases in this report and one in a previous report.  
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